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ABSTRACT 51 
Background: Antimicrobial resistance (AMR) is a global health priority. Leading UK and global 52 
strategy papers to fight AMR recognise its social and behavioural dimensions, but current policy 53 
responses to improve the popular use of antimicrobials (e.g. antibiotics) are limited to education and 54 
awareness-raising campaigns. In response to conceptual, methodological, and empirical weaknesses 55 
of this approach, we study people’s antibiotic-related health behaviour through three research 56 
questions: 57 
RQ1. What are the manifestations and determinants of problematic antibiotic use in patients’ 58 
healthcare-seeking pathways? 59 
RQ2. Will people’s exposure to antibiotic awareness activities entail changed behaviours that diffuse 60 
or dissipate within a network of competing healthcare practices? 61 
RQ3. Which proxy indicators facilitate the detection of problematic antibiotic behaviours across and 62 
within communities? 63 
Methods: We apply an interdisciplinary analytical framework that draws on the public health, medical 64 
anthropology, sociology, and development economics literature. Our research involves social surveys 65 
of treatment-seeking behaviour among rural dwellers in northern Thailand (Chiang Rai) and southern 66 
Lao PDR (Salavan). We sample approximately 4,800 adults to produce district-level representative 67 
and social network data. Additional 60 cognitive interviews facilitate survey instrument development 68 
and data interpretation. Our survey data analysis techniques include event sequence analysis (RQ1), 69 
multilevel regression (RQ1-3), social network analysis (RQ2), and latent class analysis (RQ3). 70 
Discussion: Social research in AMR is nascent, but our unprecedentedly detailed data on micro-level 71 
treatment-seeking behaviour can contribute an understanding of behaviour beyond awareness and free 72 
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choice, highlighting for example decision-making constraints, problems of marginalisation and lacking 73 
access to healthcare, and competing ideas about desirable behaviour.  74 
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SUMMARY BOX 77 
• Antimicrobial resistance (AMR) is a global health priority, and leading UK and global 78 
strategy papers recognise its social and behavioural dimensions. 79 
• Behavioural elements of these strategy papers have conceptual, methodological, and 80 
empirical weaknesses. 81 
• We will carry out social research to understand the nature of antibiotic-related treatment-82 
seeking behaviour in rural Thailand and Lao PDR. 83 
• We will conduct survey research with 4,800 adult villagers (yielding district-level 84 
representative and social network data), complemented with cognitive interviews and 85 
secondary administrative data. 86 
• Our study will contribute to the nascent yet urgently needed social research in AMR. 87 
BACKGROUND 88 
Access to non-prescription antibiotics is a widespread phenomenon in low- and middle-income 89 
countries (LMICs) [1], contributing to inappropriate medicine use, to the development of antimicrobial 90 
resistance (AMR), and potentially to the subsequent spread of resistant bacteria across the world [2]. 91 
Leading global and UK policy papers aiming to deal with the over- and misuse of antibiotics among 92 
the general population focus thereby wholly on educational and awareness-raising campaigns to 93 
encourage positive behaviour change [3-6]. Awareness-raising is important [7], but as the sole global 94 
strategy focusing on people’s healthcare-seeking behaviour (aside from public health interventions to 95 
prevent illness) it has three central weaknesses. 96 
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The first is conceptual: By limiting our attention to “awareness” as the main driver of people’s 97 
antibiotic use, we are prone to neglecting determinants of health behaviour beyond information and 98 
free choice such as economic constraint, social pressure, or local conceptions of illness [8-11]. 99 
However, little is known about how economic constraints, social discrimination, or spatial 100 
marginalisation deprive people of choices and drive them into seemingly adverse antibiotic-related 101 
behaviours, and whether and how interventions should address these constraints in the context of 102 
global AMR policy. 103 
The second is methodological: Quantitative community- and population-level analyses of antibiotic 104 
usage disregard routinely that healthcare processes involve combinations of “no care,” “self-care,” and 105 
healthcare from many different practitioners [12]. Although conceptually established and applied in 106 
qualitative research [13 14], the sequential understanding of treatment-seeking behaviour has not yet 107 
entered quantitative public health research. The majority of quantitative analyses of healthcare 108 
behaviour in low- and middle-income countries instead adopt a single-stage approach, implying that a 109 
patient “chooses” once from a portfolio of healthcare options, some of which may be more likely to 110 
involve antibiotics than others [15 16]. This conventional analysis can be useful to measure rates of 111 
antibiotic access, but their aggregate nature forgoes valuable information and obscures the factors 112 
influencing antibiotic use throughout an illness, for example the use of information technology to 113 
gather information [as we demonstrate in 17]. 114 
The third is empirical: Studies of awareness campaign effectiveness focus on knowledge gains but 115 
disregard the social mechanisms of information diffusion [see e.g. 18]. Awareness campaigns often 116 
expect information to spread within communities, but these communities are not always collaborative 117 
[19]. In addition, as a potential solution in a healthcare-seeking problem, new information about 118 
antibiotic use also competes with other ideas, some of which may represent dominant healthcare 119 
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strategies from the individual’s perspective [20].1 We do not understand sufficiently how these 120 
interdependencies play out during the diffusion process of antibiotic knowledge and practice. It 121 
therefore appears risky to confine our behavioural tactics to the single mechanism of awareness raising 122 
that is merely believed to function. 123 
In response to these conceptual, methodological, and empirical challenges, we intend to improve the 124 
understanding of patients’ antibiotic-related behaviour to support creative thinking about targeted and 125 
unconventional AMR interventions in LMICs. Three research questions will guide our enquiry: 126 
RQ1. What are the manifestations and determinants of problematic antibiotic use in patients’ 127 
healthcare-seeking pathways? 128 
RQ2. Will people’s exposure to antibiotic awareness activities entail changed behaviours that diffuse 129 
or dissipate within a network of competing healthcare practices? 130 
RQ3. Which proxy indicators facilitate the detection of problematic antibiotic behaviours across and 131 
within communities? 132 
We adhere to conventions in the field of public health when using the contentious language of 133 
“problematic” and “appropriate” behaviour. However, from a behavioural perspective, a conventional 134 
clinical definition of “problematic behaviour” is impractical to pursue because it would involve claims 135 
on the mis-/match between a patient’s condition (e.g. being caused by a particular micro-organism) 136 
and the type, dosage, duration, and affordability of the administered drugs. Patients are not necessarily 137 
                                                 
1 Information is also unlikely to remain static during the diffusion process; utilisation and (re-)interpretation of educational 
messages can alter nature, meaning, and value of this information over time and across people. Our focus on healthcare-
seeking behaviour and attitudes towards antibiotics can capture unintended behavioural responses to a limited extent, but 
our survey is unable to study the implications and mechanisms underlying such potential transformations comprehensively 
(for which qualitative and ideally ethnographic research would be better suited). We thank an anonymous reviewer for 
pointing this out. 
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able to diagnose themselves, decide whether an antibiotic is needed, and then select the clinically most 138 
suitable course of treatment. Indeed, many illnesses do not involve a doctor at all. Considering that 139 
“problematic behaviour” is subjective and context specific, we instead record patients’ behavioural 140 
trajectories during an illness and apply different evaluative criteria to make judgements of 141 
“appropriateness” flexibly and transparently. In consultation with the social anthropologists, medical 142 
practitioners, and local field staff in our study team, we will categorise individually as well as socially 143 
“appropriate” behavioural sequences that go beyond binary assessments of healthcare access or 144 
antibiotic use. For example, individually rational bypassing of referral systems could entail healthcare 145 
resource misallocation from a public health perspective, and individual antibiotic use can entail 146 
negative externalities on the societal level through potential contributions to antibiotic resistance. Our 147 
interest in human behaviour thereby does not intend to attribute blame to patients for patterns of 148 
antibiotic usage that might contribute to AMR, but rather to explore decisions and decision-making 149 
constraints on the healthcare demand side. The provision of the raw behavioural sequences will allow 150 
other researchers to make their own evaluations of health behaviours depending on their specific 151 
assessment criteria and interests. 152 
METHODS 153 
Theoretical Framework 154 
Our study departs from conventional policy assumptions that antibiotic misuse among patients stems 155 
from a lack of knowledge regarding appropriate medicine use. Instead, we frame antibiotic use as one 156 
among multiple solutions in people’s healthcare “activity space.” 157 
Contrary to existing applications of activity space frameworks in areas like disability and mobility [21-158 
23] and social geography [24-26], we do not adhere to spatial conceptualisations through which e.g. 159 
experienced space is linked to health outcomes like obesity or HIV [24 26]. Instead, we draw on 160 
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theoretical strands and techniques from the disciplines of public health, medical anthropology, 161 
sociology, and development economics, which suggest that healthcare behaviour takes place within a 162 
physical and social space populated by various healthcare providers (including drug vendors), and that 163 
this space is defined by the difficulty and the perceived and dynamically changing value of utilising 164 
any of these providers during an illness. Difficulty is determined by the tools and solutions at the 165 
patients’ disposal (e.g. social support networks, cars, communication technology), but not every 166 
solution affects access to different providers equally. In addition, patients might not be aware of every 167 
provider in their vicinity (they therefore do not enter the activity space), and some providers signal 168 
better healthcare value than others, depending on type and severity of the illness. Moreover, the activity 169 
space overlaps across patients and it is thus a shared space. These characteristics lead us to identify 170 
three key elements of antibiotic usage in a healthcare activity space: (a) the emergence of pathways 171 
through the health system during the course of an illness; (b) the co-existence of multiple solutions for 172 
the health problem, the value of which changes dynamically; and (c) cooperation, competition, and 173 
exclusion in a shared social space. As a result, our definition of activity spaces can be likened to 174 
“markets” in the strategic marketing literature [27], where markets can be delineated by different 175 
customer groups (in the case of health, e.g. different socioeconomic groups), the customer function to 176 
be served (e.g. curative care), and the “alternative solutions” available to fulfil this function (e.g. 177 
antibiotic use at home, care from primary health centre, sick leave). 178 
The breadth of the activity space framework allows us to consider multiple, and otherwise conceptually 179 
more restricted, explanatory approaches for treatment-seeking behaviour side-by-side [e.g. transaction 180 
cost approaches alongside the information deficit arguments that often underlie policy narratives; 28 181 
29]. The conceptualisation as a shared social space also permits us to go beyond conventional 182 
individualistic treatment-seeking models in order to explore new forms of health-related collective 183 
action problems. In addition, our framework permits us to examine the determinants of problematic 184 
behaviour and the positive as well as negative outcomes of technology use, rather than merely 185 
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articulating the enabling conditions of desired behaviour change as is common in the public health 186 
literature [30-32]. Activity spaces are therefore not a theory per se, but a useful analytical domain to 187 
guide our research. 188 
Research design 189 
We will carry out population- and community-level health behaviour surveys in rural Chiang Rai 190 
(Thailand) and Salavan (Lao PDR), and we collect complementary qualitative data. This will result in 191 
two survey data sets: the first contains district-level representative treatment-seeking behaviour of 192 
approx. 1,200 adults across 30 rural communities per country; the second comprises social network 193 
censuses of approx. 400 adults each in three rural communities per country. Within the sampled 194 
villages, we will complete checklists about existing formal and informal healthcare facilities and gather 195 
patient load data from primary care units catering to the respective villages. As part of the questionnaire 196 
testing process, we will conduct (and collect as primary data) cognitive interviews to improve the 197 
survey tool and to interpret our data. 198 
We will carry out the district-level village survey in one round, and the village-level social network 199 
censuses in two rounds (see Figure 1). Between the two village social network censuses, we will carry 200 
out education activities in the selected villages as part of antibiotic- and medicine-use-related public 201 
engagement. Developed after a year of qualitative health behaviour research across Southeast Asia, 202 
these small-scale activities aim to help villagers learn more about drug resistance and to help the social 203 
and medical research communities to better appreciate local people’s access to healthcare and medicine 204 
conceptions and constraints. The activities will take place after the network surveys in each of the 205 
network villages, lasting one to two days, involving approximately 30 villagers each, and including 206 
interactive sessions like trading games, poster making, storytelling, and role plays.2 The district survey 207 
                                                 
2 While we do not expect regular social networks to evolve as a result of our educational activity, we will be able to ascertain 
whether people activate different social contacts when seeking treatment before and after our activity. In addition, we will 
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will take place after the education activities, and we will subsequently re-survey all adults in the 208 
network villages (i.e. two to three months after the first network village survey round). 209 
 210 
211 
Figure 1. Study Design and Timeline. 212 
Source: Authors. 213 
Study participants 214 
Groups included in this research comprise adults (aged 18 years and above) in rural Salavan and rural 215 
Chiang Rai. We focus on Thailand and Lao PDR because they are situated in a region that experiences 216 
high rates of antibiotic use and increasing resistance [4 33 34]. Compared to Lao PDR, Thailand 217 
                                                 
also learn whether respondents who did not participate in the activity learned about it through their regular social network 
or from other contacts. 
Chiang Rai Salavan
Team training
Network census I (3 vil.)
Education activity (3 vil.)
District survey (30 vil.)
Network census II (3 vil.)
Team training
Network census I (3 vil.)
Education activity (3 vil.)
District survey (30 vil.)
Network census II (3 vil.)
Month 3
Month 4
Month 5
Month 6
Month 7
Month 8
Month 9
Month 1 after 
ethical approval
Month 2
Survey piloting and
cognitive interviews
Survey piloting and
cognitive interviews
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exhibits a more advanced economic and health system context and more established AMR 218 
stewardship. A comparative study of these low- (Lao PDR) and middle-income (Thailand) contexts 219 
therefore offers interesting lessons for domestic and global antibiotic policy. We focus on adults 220 
because they account for much of the popular antibiotic demand and typically acquire and administer 221 
antibiotics on behalf of children [35]. Lastly, we focus on rural areas of Chiang Rai and Salavan 222 
because their formal and informal health systems face relatively high infrastructural, human resource, 223 
financial, and regulatory constraints; while their inhabitants are more often characterised by economic, 224 
social, and spatial marginalisation. This does not automatically mean that our entire study population 225 
qualifies as “marginalised” since we define marginalisation in relative terms of wealth (e.g. bottom 226 
quintiles of household asset and amenity indices), social position (e.g. within village social networks), 227 
and geography (e.g. distance to urban centres). However, it is important to note that our study 228 
implications will speak to rural areas with their specific constraints and patterns of marginalisation, 229 
which are systematically different from urban settings. 230 
Data collection 231 
The district-level representative survey will be conducted in a three-stage stratified cluster random 232 
sampling design. A cluster sample is necessary to ensure the logistical and financial feasibility of the 233 
survey, and we aim to reduce its negative implications for the effective sample size through 234 
stratification, which helps to increase the information contained in each cluster [36]. The first stage 235 
involves the random selection of 30 villages (clusters) across five purposively selected districts in each 236 
site, stratified by their distance to the nearest urban centre [using data from 37]. Figure 2 depicts the 237 
resulting village samples. The second stage enumerates all residential buildings within the selected 238 
villages using satellite imagery from Google Maps and Bing Maps, of which we sample 5% of the 239 
buildings (but at least 30 houses) in a stratified interval sampling approach to ensure spatial 240 
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representativeness. During the survey implementation, the third sampling stage will select randomly 241 
one respondent for every five adults in each chosen house.  242 
 243 
244 
Figure 2. Field Sites and Sampled Villages in Thailand and Lao PDR 245 
Source: Authors, adapted from Google Inc. [38]. 2017 map data from Landsat / Copernicus. 246 
 247 
The sampling strategy for the community-level social network census surveys involves the purposive 248 
selection of three comparable villages in both countries. Selected in consultation with local 249 
stakeholders, guiding criteria for selection were (a) village size and structure, (b) remoteness and road 250 
accessibility, (c) economic status as approximated by village-level infrastructure and facilities, (d) 251 
ethnic composition, and (e) number and location of health facilities within a 2km radius. The villages 252 
are estimated to have a size of 100 to 200 households with 2.9 adults per rural household in Lao PDR 253 
(ranging from 1.8 to 4.6 per village) and 2.4 in Thailand on average [ranging from 1.6 to 4.3 per village; 254 
a) Chiang Rai
b) Salavan
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39 40]. Within the selected communities, all households will be approached, their adult members 255 
enumerated, and invited to participate. 256 
Our survey instrument will be a 45-minute questionnaire that captures people’s complex healthcare-257 
seeking pathways and their medicine use therein. An important feature of this instrument is the 258 
collection of self-reported sequential healthcare pathway data for acute illnesses and accidents that 259 
occurred in the two months prior to the interview. As shown in Figure 3, we will subdivide an illness 260 
into discrete steps of activities and record their type, duration, and location; with whom the patient 261 
interacted during the healthcare activity; whether the patient used any medicines during the step 262 
(elicited using a “drug card” containing the most common local medicines), their source, and how 263 
long, often, and at what dosage they were taken; and whether, why, and by whom any kind of health-264 
related mobile phone, Internet, media, or vehicle use took place.3 We also collect data on the social 265 
and economic background of the respondents as well as information about people’s existing 266 
conceptions of and attitudes towards antibiotics. In the case of the social network censuses, we will 267 
ask additional questions to construct four different kinds of (health-related) social networks: 268 
a) (Health) communication networks: People within and outside the village with whom the 269 
respondent interacts and talks about health (elicited in first network survey round). 270 
b) Incidence network: Places where the respondent typically interacts with other villagers (elicited 271 
in first network survey round).  272 
c) Help network: Contacts who are activated during an illness (elicited in both network survey 273 
rounds). 274 
                                                 
3 Due to language ambiguities in the term “antibiotic,” we do not ask people directly whether they took an antibiotic, but 
rather which medicine they received and used at each step in the treatment-seeking process. Pilot interviews suggested that 
a part of the rural population is able to describe medicine unambiguously (e.g. using colloquial or technical terms for 
antibiotics), while other groups do not know what medicine they received. In the latter case, we triangulate their responses 
with their descriptions of antibiotics (e.g. as “sore throat medicine,” which we also capture in the questionnaire), and we 
ask for descriptions of these medicines (e.g. “a shot,” “a green-blue capsule”). We then code the medicines for sensitivity 
analysis into categories “likely to be an antibiotic,” “unlikely to be an antibiotic,” and “cannot ascertain type of medicine” 
according to common medicines used in the field sites. 
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d) Information network: People with whom the respondent talked about the public engagement 275 
activity (elicited in second network survey round). 276 
The questionnaire will be administered through tablet-based electronic data collection by locally 277 
recruited survey teams comprising six enumerators and two survey supervisors per country. The survey 278 
period will be between November 2017 and April 2018, which is the post-rice-harvest dry season in 279 
both field sites. This season was chosen for village accessibility (landslides and floods are common 280 
during the rainy season) and the availability of villagers for interviews (villagers often reside 281 
temporarily near their rice fields during the planting and harvest seasons). Due to the temporal focus 282 
on one season, our survey is therefore not able to capture seasonal change affecting the epidemiological 283 
environment, internal migration, healthcare-seeking patterns, and interactions within social networks. 284 
 285 
286 
Figure 3. Example of Treatment-Seeking Pathway Data Collected in the Survey. 287 
Source: Authors, adapted from [41]. 288 
 289 
We will pilot the questionnaire to identify respondents’ understanding of the survey questions and the 290 
range of possible answers. Between 10 and 30 one-hour cognitive interviews per site will support this 291 
process and enable insights into how respondents understand survey questions and how they arrive at 292 
their answers [42]. The qualitative data generated through the cognitive interviews will also facilitate 293 
the interpretation of the quantitative survey results. 294 
Step 1
•Self-care / rest
•At home
•3 days
•Called relative to 
talk about 
discomfort
Step 2
• Informal healer
•At home
•8 days
•Paracetamol (1 
daily, for 3 days)
Step 3
•Public county 
hospital
• > 2 hours from 
home
• 14 days
• Called taxi
Step 4
•Private doctor
•10 minutes from 
home
•1 day
•Phenoxymethyl-
penicillin (half 
dose daily, for 1 
day)
Step 5
•Self-care / rest
•At home
•7 days
•Phenoxymethyl-
penicillin (half 
dose daily, for 7 
days)
Process Data
Symptoms | Diagnosis | Self-perceived severity | Total duration | Start date | Current status | People involved
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Two further sources of data will complement our survey data. First, in order to understand antibiotic-295 
seeking behaviour in the local health systems, separate checklists will help us to gather observational 296 
information about the location of formal and informal healthcare providers in each village. Secondly, 297 
we will estimate patient load and peak demand for public healthcare services by accessing secondary 298 
administrative data from public primary care facilities that cater to the sampled villages. 299 
Analysis 300 
The data analysis techniques to inform our research questions include:  301 
• RQ1: Sequence analysis to describe and understand linear series of events [41 43 44],  302 
• RQ1-3: Multilevel regression analysis to test the relationship between antibiotic use as a 303 
dependent variable, and a range of established determinants of treatment-seeking behaviour as 304 
independent variables [45], 305 
• RQ2: Social network analysis (network-based event history and relational event sequence 306 
analysis) to examine how behaviours and beliefs across a social network relate to individual 307 
behaviours and beliefs, and how this relationship persists over time [46-48], and  308 
• RQ3: Latent class analysis to identify (a) common symptoms associated with problematic 309 
antibiotic usage, (b) the characteristics of populations who are likely to exhibit problematic 310 
antibiotic behaviours, and (c) contextual conditions predicting adverse behaviours, all of which 311 
may help guide future interventions and policies [49].  312 
Related in particular to Research Questions 1 and 2, we will further examine six hypotheses about 313 
antibiotic use among the general population: 314 
H1. Marginalised groups have fewer means to access formal treatment, which increases their 315 
likelihood to rely on over-the-counter medicines including antibiotics as an alternative solution. 316 
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H2. Technology use increases access to formal healthcare providers but is directed towards those 317 
who are more inclined to prescribe antibiotics.4 318 
H3. Awareness about “rational antibiotic use” alone has only a minor influence on antibiotic usage 319 
behaviour if patients are economically, socially, or spatially marginalised. 320 
H4. In the absence of competing healthcare practices, new antibiotic-related behaviours diffuse 321 
through social networks. 322 
H5. Pre-existing competing practices subdue the spread of new antibiotic-related behaviours within 323 
the community network if no “critical mass” can be achieved. 324 
H6. Peak demand for scarce high-quality healthcare providers drives less competitive (i.e. more 325 
marginalised) patients into behaviours that are more likely to involve adverse antibiotic use. 326 
Note that these hypotheses do not intend to declare the behaviour of marginalised groups to be 327 
“irrational.” Rather, we hypothesise that the behaviour of marginalised groups is subject to greater 328 
healthcare access constraints, owing to which antibiotic use might be more likely. Whether this is 329 
indeed the case, and whether these behaviours are less appropriate than otherwise, are empirical 330 
questions that we hope to inform through our survey. 331 
DISCUSSION 332 
Ethical Considerations 333 
Informed Consent 334 
We received a waiver for written consent requirements in order to not unfairly exclude illiterate 335 
population sub-groups in our field sites [50], and to ensure trust between the researcher and the rural 336 
                                                 
4 The interest in technology use is rooted in our activity space framework, according to which different healthcare providers 
(e.g. private doctors) are more responsive to patients’ use of e.g. mobile phones, which can affect treatment-seeking 
pathways and, potentially, antibiotic use. 
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respondents [51]. Instead of participant-dated signature, we follow a verbal consent process in which 337 
(1) we seek permission from village leaders to carry out our survey in their villages; (2) the survey 338 
fieldworker reads out (and records on audio tape) an oral consent script to the potential respondent and 339 
provides them with a printed copy of the Participant Information Sheet; (3) the survey fieldworker asks 340 
the respondent to state her or his consent, name, and date on audio record; and (4) the survey 341 
fieldworker personally signs and dates a written record of oral consent. We provide a detailed 342 
justification and explanation of this verbal consent process in Appendix 1. 343 
Privacy and Confidentiality 344 
Further ethical considerations in this study relate to privacy and confidentiality. The data collected in 345 
this study include self-reported health and economic information. Personal contact details will be 346 
stored separately from the data sets in order to match data from repeated network survey rounds. Any 347 
identifying information will be deleted from the analytical data set or coded into anonymous 348 
respondent numbers for the social network census survey data set. Geographical data allowing 349 
household identification will be translated into distance measures and a village-centred metric 350 
coordinate system (similar to the Universal Transverse Mercator system). Should village layouts prove 351 
idiosyncratic so that the metric coordinate system enables identification, we will withdraw these data 352 
from the data sets. 353 
Proposed Impact 354 
The academic impact of our study pertains to antibiotic-related behaviour and its relationship to 355 
marginalisation, technology, and social relationships. Our innovations therein are theoretical 356 
(development of the activity space framework to conceptualise and situate people’s antibiotic access 357 
and use during illness), methodological (sequence analysis for healthcare pathways), and empirical 358 
(novel insights into the impact of marginalisation, technology, and knowledge on antibiotic usage). In 359 
addition, we will build capacity for social research in AMR for instance through four internships for 360 
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local candidates from Southeast Asia who consider interdisciplinary academic careers, and our project 361 
aims to influence the global health discourse about AMR for example by hosting four eight-week 362 
student placements with the MSc International Health and Tropical Medicine (IHTM; a global health 363 
degree at the University of Oxford).  364 
In conclusion, social research in AMR is nascent, but our unprecedentedly detailed data on micro-level 365 
treatment-seeking behaviour promises to contribute to understanding behaviour beyond awareness and 366 
free choice, highlighting for example decision-making constraints, problems of marginalisation and 367 
lacking access to healthcare, and competing ideas about desirable behaviour.  368 
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